Zolmitriptan
Zomig, Zomig-zmt (zolmitriptan) is a small molecule pharmaceutical. Zolmitriptan was first approved as Zomig on 1997-11-25. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1F, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Zomig, Zomig-zmt (generic drugs available since 2013-05-14)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zolmitriptan | ANDA | 2023-06-20 |
| zomig | ANDA | 2022-03-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 3 | — | 3 | — | 6 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | 1 | 2 | — | — | — | 2 | |
| Lung neoplasms | D008175 | C34.90 | — | 2 | — | — | — | 2 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | J84.10 | 1 | 1 | — | — | — | 1 | |
| Hermanski-pudlak syndrome | D022861 | E70.331 | 1 | 1 | — | — | — | 1 | |
| Oculocutaneous albinism | D016115 | E70.32 | 1 | 1 | — | — | — | 1 | |
| Platelet storage pool deficiency | D010981 | EFO_1001112 | 1 | 1 | — | — | — | 1 | |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | 1 | — | — | — | 1 | |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 2 | — | — | — | — | 2 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ZOLMITRIPTAN |
| INN | zolmitriptan |
| Description | Zolmitriptan is a member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is a member of tryptamines and an oxazolidinone. It is functionally related to a N,N-dimethyltryptamine. |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 139264-17-8 |
| RxCUI | 135775 |
| ChEMBL ID | CHEMBL1185 |
| ChEBI ID | 10124 |
| PubChem CID | 60857 |
| DrugBank | DB00315 |
| UNII ID | 2FS66TH3YW (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,496 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
209 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more